SPARC2026-01-012026-03-31SPARC2026-03-31SPARC2025-03-31SPARC2025-04-012026-03-31SPARC2026-01-012026-03-31in-capmkt:OtherExpenses1MemberSPARC2026-01-012026-03-31in-capmkt:OtherExpenses2MemberSPARC2026-01-012026-03-31in-capmkt:OtherExpenses3MemberSPARC2025-04-012026-03-31in-capmkt:OtherExpenses1MemberSPARC2025-04-012026-03-31in-capmkt:OtherExpenses2MemberSPARC2025-04-012026-03-31in-capmkt:OtherExpenses3MemberSPARC2026-03-31OtherNoncurrentFinancialAssetsDomain1SPARC2026-03-31OtherNoncurrentAssetsDomain1SPARC2026-03-31OtherNoncurrentAssetsDomain2SPARC2026-03-31OtherCurrentFinancialAssetsDomain1SPARC2026-03-31OtherCurrentAssetsDomain1SPARC2026-03-31OtherNoncurrentFinancialLiabilitiesDomain1SPARC2026-03-31OtherNoncurrentFinancialLiabilitiesDomain2SPARC2026-03-31OtherNoncurrentLiabilitiesDomain1SPARC2026-03-31OtherCurrentFinancialLiabilitiesDomain1SPARC2026-03-31OtherCurrentFinancialLiabilitiesDomain2SPARC2026-03-31OtherCurrentLiabilitiesDomain1SPARC2026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1SPARC2026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2SPARC2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1SPARC2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2SPARC2026-01-012026-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares532872SPARCNAINE232I01014Sun Pharma Advanced Research Company LimitedMain BoardEquity2025-04-012026-03-312026-05-182026-05-11INRLakhsQuarterlyFourth quarterSingle segmentPharmaceutical Research and Development2026-05-1817:30:002026-05-1819:00:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated18532200000180000001855020000051600000002602000001164000002400000048840000094060000017609600000017609600000-38000000-38000000176134000000000176134000001350000017626900000176269000000135000000324500000154.2700054.2700001. These audited consolidated financial results relate to Sun Pharma Advanced Research Company Limited (the 'Company') and its Wholly Owned Subsidiaries (together the ‘Group’) and are prepared by applying Ind AS 110 - "Consolidated Financial Statements". <BR> <BR> 2.The above audited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 18, 2026. <BR> <BR> 3.The above audited consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. <BR> <BR> 4.The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. <BR> <BR> 5.During the quarter, the Group recognised income of INR 184,002 lakhs in respect of a Priority Review Voucher (PRV) granted by the United States Food and Drug Administration (USFDA) on February 03, 2026 for Sezaby®. The PRV, being a transferable instrument, was subsequently sold by the Group on April 30, 2026 for USD 195 million. <BR> <BR> The PRV has been accounted as a non- monetary government grant under Ind AS 20 and the fair value of the PRV has been recognised in the Statement of Profit and Loss. <BR> <BR> 6.The Group has only one reportable business segment namely 'Pharmaceutical Research and Development'. <BR> <BR> 7. The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the relevant financial years which were subject to limited review by the Statutory Auditors of the Group.2025-04-012026-03-31AuditedConsolidated18791700000109500000189012000002360000000011803000003413000001021000001387800000324750000015653700000-12360000015530100000-19000000-1900000015532000000000015532000000257000001555770000015557700000025700000032450000011338820000047.8600047.860000Clinical trial expenses / products development expense28400000Professional charges293000000Other expenses167000000Clinical trial expenses / products development expense226600000Professional charges694800000Other expenses46640000085180000050000000013000007121000000000028740000028740000022700000120410000030844000000082700000116000000170000014600000110600000545000001845910000018624200000217086000003245000001306370000013388200000013388200000000030100000301000001234000000062600000077950000055614000001300000095850000097150000079740000073303000008210000012850000000754090000000832040000021708600000Other financial assets287400000Income tax assets (net)293200000Other non-current assets910900000Other financial assets14600000Other current assets18459100000Lease liabilities16600000Other financial liabilities13500000Other non-current liabilities626000000Lease liabilities15100000Other financial liabilities782300000Other current liabilities821000003413000000826000000-185856000000000-1822000000-800000000102100000011940000000073500000010290000000000-24000000-18234200000-2704100000000-3164000000-238770000000000000300000023830000000000000000000000030000000-235000000000000002115810000018178500000235000000342200000002613900000-8800000800000-80000001960000011600000Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on employee defined benefit plan)10700000Items that may be reclassified to profit or loss (exchange differences in translating the financial statements of subsidiary)280000013500000Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on employee defined benefit plan)20700000Items that may be reclassified to profit or loss (exchange differences in translating the financial statements of subsidiary)500000025700000001350000025700000AuditedtrueSRBC AND CO LLPtrue2029-02-28